임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
48건 표시
- 2상모집 중· Cytokine Release SyndromeInfliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
협력: 얀센(J&J)
- 2상모집 중· Carcinoma, Non-Small-Cell LungA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
리드: 얀센(J&J)
- 2상모집 예정· Multiple Myeloma (MM)MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
협력: 얀센(J&J)
- 2상모집 중· Multiple MyelomaA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중· Dermatitis, AtopicA Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
리드: 얀센(J&J)
- 2상모집 중· Arthritis, PsoriaticA Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
리드: 얀센(J&J)
- 2상모집 중· Multiple Myeloma (MM)Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
협력: 얀센(J&J)
- 2상모집 중· Multiple Myeloma in RelapseSubcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
협력: 얀센(J&J)
- 2상모집 중· Multiple MyelomaA Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
리드: 얀센(J&J)
- 2상모집 중· AL AmyloidosisA Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Depressive Disorder, MajorA Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· X-Linked Retinitis PigmentosaA Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중· Multiple MyelomaA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Alzheimer DiseaseA Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
리드: 얀센(J&J)
- 2상모집 중· Multiple MyelomaBispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
협력: 얀센(J&J)
- 2상모집 중· Leukemia, Lymphocytic, Chronic, B-CellA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
리드: 얀센(J&J)
- 2상모집 중· Pulmonary TuberculosisPlatform Assessing Regimens and Durations In a Global Multisite Consortium for TB
협력: GSK, 얀센(J&J)
- 2상모집 중· Multiple MyelomaStudy of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· High-Risk de Novo Multiple MyelomaTeclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungPremedication to Reduce Amivantamab Associated Infusion Related Reactions
리드: 얀센(J&J)
- 2상모집 중· Carcinoma, Non-small-Cell LungA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Colitis, UlcerativeA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
리드: 얀센(J&J)
- 2상모집 중· High-risk Smoldering Multiple MyelomaImmuno-PRISM (PRecision Intervention Smoldering Myeloma)
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Crohn's DiseaseA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· MyositisA Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· AmyloidosisA Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
리드: 얀센(J&J)
- 2상모집 중· Hematological MalignanciesA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Aggressive Variant Prostate CarcinomaCabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Urinary Bladder NeoplasmsA Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Prostatic NeoplasmsAdjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Hematological MalignanciesA Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaDaratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
협력: 암젠, 얀센(J&J)
- 2상모집 중단 (진행 중)· Leukemia, Myeloid, AcuteA Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
리드: 애브비 · 협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Prostatic Neoplasms, Castration-ResistantA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Urothelial CancerAn Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
리드: 얀센(J&J)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.